BioPharmSignal logoBioPharmSignal

Biotech News

IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio (INAB)IN8bioConference / presentation

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and

Related news

INABIN8bio2026-09-10 12:00 EST

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

INABIN8bio2026-10-06 20:00 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

View all latest news

IN8bio

Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...

Recent company news

INABIN8bio2026-10-06 20:00 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INABIN8bio2026-09-22 20:00 EST

IN8bio to Present at Sidoti Small-Cap Virtual Conference

INABIN8bio2026-09-10 12:00 EST

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

INABIN8bio2026-09-09 12:00 EST

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

INABIN8bio2026-08-10 20:01 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
1.39 USD
Market cap
14.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States